Integrated Wealth Concepts’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Integrated Wealth Concepts’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,000	Closed	-$86.9K	–	2552
2026 Q1	$86.9K	Buy	+12,000	New	+$96.6K	﹤0.01%	2192
2025 Q4	–	Sell	-12,000	Closed	-$70.8K	–	2067
2025 Q3	$70.8K	Buy	+12,000	New	+$65.3K	﹤0.01%	1932

Other funds holding EPRX

Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Integrated Wealth Concepts's EPRX Position: Q2 2026 in Review

Integrated Wealth Concepts sold out of Eupraxia Pharmaceuticals (EPRX) in Q2 2026, closing a stake of 12,000 shares — an estimated $86.9K sold.

Integrated Wealth Concepts first reported a position in EPRX in Q3 2025 and held it in 2 quarters. The position peaked at $86.9K in Q1 2026. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

Integrated Wealth Concepts reported no remaining Eupraxia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Integrated Wealth Concepts sold 12,000 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $86.9K.
Integrated Wealth Concepts first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Integrated Wealth Concepts's Eupraxia Pharmaceuticals position peaked at $86.9K in Q1 2026.
67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.